Skip to main content
SpringerLink
Log in

Industry Pulse

Editorial Development By Adis International Limited, Italy

  • Industry Pulse
  • Published:
High Blood Pressure & Cardiovascular Prevention Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. Santini M, De Ferrari GM, Pandozi C, et al. Atrial fibrillation requiring urgent medical care. Approach and outcome in the various departments of admission. Data from the atrial Fibrillation/flutter Italian REgistry (FIRE). Ital Heart J 2004 Mar; 5(3): 205–13

    PubMed  Google Scholar 

  2. Pedersen OD, Bagger H, Kober L, et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999 Jul 27; 100(4): 376–80

    Article  PubMed  CAS  Google Scholar 

  3. Vermes E, Tardif JC, Bourassa MG, et al.. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003 Jun 17; 107(23): 2926–31

    Article  PubMed  Google Scholar 

  4. Dahlöf B, Devereux RB, Kjeldsen S, et al.; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For End Point reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 955–1003

    Google Scholar 

  5. Wachtell K, Hornestam B, Lehto M, et al. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45: 705–11

    Article  PubMed  Google Scholar 

  6. Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces newonset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45: 712–9

    Article  PubMed  CAS  Google Scholar 

  7. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047–53

    Article  PubMed  Google Scholar 

  8. Phillips DI, Barker DJ, Hales CN, et al. Thinness at birth and insulin resistance in adult life. Diabetologia 1994; 37: 150–4

    Article  PubMed  CAS  Google Scholar 

  9. Eriksson JG, Forsen T, Tuomilehto J, et al. Effect of size at birth and childhood growth on insulin resistance syndrome in elderly individuals. Diabetology 2002; 45: 342–8

    Article  CAS  Google Scholar 

  10. American Diabetes Association and National Institute of Diabetes, Digestive and Kidney Diseases. The prevention or delay of type 2 diabetes. Diabetes Care 2002; 25: 742-9

    Google Scholar 

  11. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002 Dec 17; 106 (25): 3143-421

  12. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403

    Google Scholar 

  13. Diabetes Prevention Program Research Group. Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care 2003; 26: 2518-23

    Google Scholar 

  14. Chiasson J, Josse R, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM (study to prevent non-insulin-dependent diabetes mellitus) randomised trial. Lancet 2002; 359: 2072–7

    Article  PubMed  CAS  Google Scholar 

  15. Chiasson J, Josse R, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM (study to prevent non-insulin-dependent diabetes mellitus) trial. JAMA 2003; 290: 486–94

    Article  PubMed  CAS  Google Scholar 

  16. Tuomilehto J, Lindstrom J, Eriksson J, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343–50

    Article  PubMed  CAS  Google Scholar 

  17. Hu G, Lindstrom J, Valle TT, et al. Physical activity, body mass index, and risk of type 2 patients with normal or impaired glucose regulation. Arch Intern Med 2004; 164: 892–6

    Article  PubMed  Google Scholar 

  18. Hu FB, Manson JE, Stampfer MJ, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001; 345: 790–7

    Article  PubMed  CAS  Google Scholar 

  19. Buchanan T, Xiang A, Peters R, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002; 51: 2796–803

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Industry Pulse. High Blood Press Cardiovasc Prev 12, 239–243 (2005). https://doi.org/10.2165/00151642-200512040-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151642-200512040-00006

Search

Navigation